Cartesian Therapeutics, Inc.
RNAC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $1 | -$1 |
| % Growth | 51.7% | -72.9% | 244.9% | – |
| Cost of Goods Sold | $13 | $0 | $0 | $0 |
| Gross Profit | -$12 | $0 | $1 | -$1 |
| % Margin | -2,731.2% | 100% | 100% | 100% |
| R&D Expenses | $14 | $15 | $15 | $11 |
| G&A Expenses | $7 | $7 | $8 | $7 |
| SG&A Expenses | $8 | $7 | $8 | $7 |
| Sales & Mktg Exp. | $1 | $0 | $0 | $0 |
| Other Operating Expenses | -$13 | $0 | $0 | $8 |
| Operating Expenses | $9 | $22 | $23 | $26 |
| Operating Income | -$21 | -$22 | -$22 | -$27 |
| % Margin | -4,660.6% | -7,319.1% | -1,989.9% | 3,521.9% |
| Other Income/Exp. Net | -$15 | $38 | $4 | $17 |
| Pre-Tax Income | -$36 | $16 | -$18 | -$10 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$36 | $16 | -$18 | -$10 |
| % Margin | -7,942.9% | 5,330.9% | -1,610% | 1,350.9% |
| EPS | -1.38 | 0.61 | -0.68 | -0.069 |
| % Growth | -326.2% | 189.7% | -885.5% | – |
| EPS Diluted | -1.38 | 0.6 | -0.68 | -0.069 |
| Weighted Avg Shares Out | 26 | 26 | 26 | 26 |
| Weighted Avg Shares Out Dil | 26 | 26 | 26 | 26 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $2 | $2 | $7 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $0 |
| EBITDA | -$35 | $16 | -$21 | -$9 |
| % Margin | -7,808.8% | 5,528.5% | -1,884.8% | 1,249% |